臺灣血液透析實作指引 (TW HD IG)
0.0.2 - ci-build
臺灣血液透析實作指引 (TW HD IG) - Local Development build (v0.0.2) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Draft as of 2026-06-11 |
<ConceptMap xmlns="http://hl7.org/fhir">
<id value="epo-type-map"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ConceptMap epo-type-map</b></p><a name="epo-type-map"> </a><a name="hcepo-type-map"> </a><p>Mapping from <a href="ValueSet-epo-type-vs.html">EPO 種類 值集 (epo-type-vs)</a> to <a href="ValueSet-epo-type-atc-vs.html">EPO 種類 ATC (Erythropoiesis-Stimulating Agent)</a></p><br/><p><b>Group 1 </b>Mapping from <a href="CodeSystem-epo-type.html">EPO 種類 (epo-type)</a> to <a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-WC.html">WHO ATC</a></p><table class="grid"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td></tr><tr><td>1 (Epoepin-a (Eprex))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#wider" title="wider">maps to wider concept</a></td><td>B03XA01 (erythropoietin)</td></tr><tr><td>2 (Epoepin-b (Recormon))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#wider" title="wider">maps to wider concept</a></td><td>B03XA01 (erythropoietin)</td></tr><tr><td>3 (Darbepoepin-a (Nesp))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>B03XA02 (darbepoetin alfa)</td></tr><tr><td>4 (Glycol-epoetin-b (Mircera))</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent" title="equivalent">is equivalent to</a></td><td>B03XA03 (methoxy polyethylene glycol-epoetin beta)</td></tr><tr><td>9 (其它 EPO)</td><td><a href="http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#wider" title="wider">maps to wider concept</a></td><td>B03XA (Other antianemic preparations)</td></tr></table></div>
</text>
<url value="https://fhir.muen.tw/ig/hd/ConceptMap/epo-type-map"/>
<version value="0.0.2"/>
<name value="EpoTypeMap"/>
<title value="EPO 種類對照表 (KiDiT → WHO ATC)"/>
<status value="draft"/>
<experimental value="true"/>
<date value="2026-06-11"/>
<publisher value="沐恩生醫光電股份有限公司"/>
<contact>
<name value="沐恩生醫光電股份有限公司"/>
<telecom>
<system value="url"/>
<value value="https://www.muenai.com/"/>
</telecom>
<telecom>
<system value="email"/>
<value value="[email protected]"/>
</telecom>
</contact>
<description
value="KiDiT『EPO 種類』本地碼對應 WHO ATC(ATC 將各 epoetin 統歸 B03XA01)。"/>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="TW"/>
</coding>
</jurisdiction>
<sourceCanonical value="https://fhir.muen.tw/ig/hd/ValueSet/epo-type-vs"/>
<targetCanonical
value="https://fhir.muen.tw/ig/hd/ValueSet/epo-type-atc-vs"/>
<group>
<source value="https://fhir.muen.tw/ig/hd/CodeSystem/epo-type"/>
<target value="http://www.whocc.no/atc"/>
<element>
<code value="1"/>
<display value="Epoepin-a (Eprex)"/>
<target>
<code value="B03XA01"/>
<display value="erythropoietin"/>
<equivalence value="wider"/>
</target>
</element>
<element>
<code value="2"/>
<display value="Epoepin-b (Recormon)"/>
<target>
<code value="B03XA01"/>
<display value="erythropoietin"/>
<equivalence value="wider"/>
</target>
</element>
<element>
<code value="3"/>
<display value="Darbepoepin-a (Nesp)"/>
<target>
<code value="B03XA02"/>
<display value="darbepoetin alfa"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="4"/>
<display value="Glycol-epoetin-b (Mircera)"/>
<target>
<code value="B03XA03"/>
<display value="methoxy polyethylene glycol-epoetin beta"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="9"/>
<display value="其它 EPO"/>
<target>
<code value="B03XA"/>
<display value="Other antianemic preparations"/>
<equivalence value="wider"/>
</target>
</element>
</group>
</ConceptMap>